A newly published research has confirmed that catheters of Teleflex Inc (TFX), which are protected with ARROWg+ard Technology, can significantly reduce bloodstream infections while also lowering the cost of treatments associated with infections.
The research entailed studying different kind of Central Venous Catheters (CVCs) inserted into the femoral area. The aim was to evaluate if a chlorhexidine/silver sulfadiazine CVC can effectively reduce bloodstream infection rates as well as the cost of diagnosing and treating an infection.
In the course of the study, patients were admitted to the Hospital Universitario de Canarias in Spain. The study examined a total of 254 catheters and 2,195 catheter days.
Results pointed to the fact that the ARROW CVC with ARROWg+ard Technology is much better equipped than an unprotected CVC, both in terms of infection reduction and total cost per patient. The protected catheter managed to achieve a zero infection rate per 1,000 catheter days, whereas the unprotected one had a much higher Catheter-related bloodstream infection (CRBSI) rate of 8.61/1,000 catheter days. Also, the antimicrobial protected catheter is able to gain a longer CRBSI-free time.
We believe that these data will help Teleflex to successfully showcase its advanced products, which will in turn attract new customers. This will eventually drive top-line growth, going forward.
Moreover, strategic partnerships are also expected to drive overall results. Teleflex recently partnered with HealthTrust covering PICC (peripherally inserted central catheter) and tip location devices. Per the agreement, members of HealthTrust will gain access to the entire range of Teleflex’s ARROW PICC and tip location devices, which includes the ARROW PICC with Chlorag+ard Technology and the ARROW VPS Vascular Positioning System.
In addition, partnerships with Premier and Amerinet are also expected to help Teleflex gain better penetration in hospitals and various treatment centers.
Zacks Rank
Teleflex currently retains a Zacks Rank #3 (Hold). Better-ranked stocks in the medical instruments industry include Inogen (INGN), Synergetics USA (SURG) and ABIOMED (ABMD). While Inogen and Synergetics USA sport a Zacks Rank #1 (Strong Buy), ABIOMED carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment